TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis TREMFYA is the first and only biologic approved for the treatment of active psoriatic arthritis t... Biopharmaceuticals, FDA Janssen Pharmaceutical, Johnson & Johnson, TREMFYA, guselkumab, PsA
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news